Functional analysis of monocarboxylate transporter 8 mutations in Japanese Allan-Herndon-Dudley syndrome patients
Open Access
- 1 January 2019
- journal article
- research article
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 66 (1), 19-29
- https://doi.org/10.1507/endocrj.ej18-0251
Abstract
Monocarboxylate transporter 8 (MCT8) facilitates T3 uptake into cells. Mutations in MCT8 lead to Allan-Herndon-Dudley syndrome (AHDS), which is characterized by severe psychomotor retardation and abnormal thyroid hormone profile. Nine uncharacterized MCT8 mutations in Japanese patients with severe neurocognitive impairment and elevated serum T3 levels were studied regarding the transport of T3. Human MCT8 (hMCT8) function was studied in wild-type (WT) or mutant hMCT8-transfected human placental choriocarcinoma cells (JEG3) by visualizing the locations of the proteins in the cells, detecting specific proteins, and measuring T3 uptake. We identified 6 missense (p.Arg445Ser, p.Asp498Asn, p.Gly276Arg, p.Gly196Glu, p.Gly401Arg, and p.Gly312Arg), 2 frameshift (p.Arg355Profs*64 and p.Tyr550Serfs*17), and 1 deletion (p.Pro561del) mutation(s) in the hMCT8 gene. All patients exhibited clinical characteristics of AHDS with high free T3, low-normal free T4, and normal-elevated TSH levels. All tested mutants were expressed at the protein level, except p.Arg355Profs*64 and p.Tyr550Serfs*17, which were truncated, and were inactive in T3 uptake, excluding p.Arg445Ser and p.Pro561del mutants, compared with WT-hMCT8. Immunocytochemistry revealed plasma membrane localization of p.Arg445Ser and p.Pro561del mutants similar with WT-hMCT8. The other mutants failed to localize in significant amount(s) in the plasma membrane and instead localized in the cytoplasm. These data indicate that p.Arg445Ser and p.Pro561del mutants preserve residual function, whereas p.Asp498Asn, p.Gly276Arg, p.Gly196Glu, p.Gly401Arg, p.Gly312Arg, p.Arg355Profs*64, and p.Tyr550Serfs*17 mutants lack function. These findings suggest that the mutations in MCT8 cause loss of function by reducing protein expression, impairing trafficking of protein to plasma membrane, and disrupting substrate channel.Keywords
This publication has 39 references indexed in Scilit:
- Insights into molecular properties of the human monocarboxylate transporter 8 by combining functional with structural informationThyroid Research, 2011
- Essential Molecular Determinants for Thyroid Hormone Transport and First Structural Implications for Monocarboxylate Transporter 8*Online Journal of Public Health Informatics, 2010
- Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretionJCI Insight, 2010
- Neuronal 3 ',3,5-Triiodothyronine (T-3) Uptake and Behavioral Phenotype of Mice Deficient in Mct8, the Neuronal T-3 Transporter Mutated in Allan-Herndon-Dudley SyndromeJournal of Neuroscience, 2009
- Importance of Monocarboxylate Transporter 8 for the Blood-Brain Barrier-Dependent Availability of 3,5,3′-Triiodo-l-ThyronineEndocrinology, 2009
- MCT8 mutation analysis and identification of the first female with Allan–Herndon–Dudley syndrome due to loss of MCT8 expressionEuropean Journal of Human Genetics, 2008
- Genotype-Phenotype Relationship in Patients with Mutations in Thyroid Hormone Transporter MCT8Endocrinology, 2008
- Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporterEuropean Journal of Pediatrics, 2007
- The MCT8 thyroid hormone transporter and Allan–Herndon–Dudley syndromeBest Practice & Research Clinical Endocrinology & Metabolism, 2007
- Mechanisms of Disease: psychomotor retardation and high T3 levels caused by mutations in monocarboxylate transporter 8Nature Clinical Practice Endocrinology & Metabolism, 2006